Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
AstraZeneca Licenses Merck Cancer Drug
by Lisa M. Jarvis
September 16, 2013
| A version of this story appeared in
Volume 91, Issue 37
AstraZeneca will shell out $50 million for global access to Merck & Co.’s MK-1775, a WEE1 kinase inhibitor in Phase IIa studies for the treatment of ovarian cancer. Preclinical studies suggest MK-1775, which blocks a protein involved in the regulation of the cell-division cycle, could enhance the efficacy of chemotherapies that work by damaging tumor DNA. The deal expands AstraZeneca’s ovarian cancer development pipeline, which includes olaparib. Olaparib blocks PARP, an enzyme involved in DNA repair. Earlier this month, the drug entered Phase III studies.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter